Aion Therapeutic Stock Profit Margin
| ANTCF Stock | USD 0.01 0 84.21% |
Aion Therapeutic fundamentals help investors to digest information that contributes to Aion Therapeutic's financial success or failures. It also enables traders to predict the movement of Aion Pink Sheet. The fundamental analysis module provides a way to measure Aion Therapeutic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aion Therapeutic pink sheet.
Aion |
Aion Therapeutic Company Profit Margin Analysis
Aion Therapeutic's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Aion Therapeutic has a Profit Margin of 0.0%. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Aion Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aion Therapeutic's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aion Therapeutic could also be used in its relative valuation, which is a method of valuing Aion Therapeutic by comparing valuation metrics of similar companies.Aion Therapeutic is currently under evaluation in profit margin category among its peers.
Aion Fundamentals
| Return On Equity | -4.17 | |||
| Return On Asset | -0.96 | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 147.3 M | |||
| Shares Owned By Insiders | 17.68 % | |||
| Price To Book | 5.77 X | |||
| Gross Profit | (1.5 K) | |||
| EBITDA | (3.68 M) | |||
| Net Income | (3.82 M) | |||
| Cash And Equivalents | 1.85 K | |||
| Total Debt | 643.8 K | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 0.15 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (1.35 M) | |||
| Earnings Per Share | (0.04) X | |||
| Beta | 0.29 | |||
| Market Capitalization | 1.47 M | |||
| Total Asset | 150.14 K | |||
| Z Score | -78.0 | |||
| Net Asset | 150.14 K |
About Aion Therapeutic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aion Therapeutic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aion Therapeutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aion Therapeutic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Aion Pink Sheet
Aion Therapeutic financial ratios help investors to determine whether Aion Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aion with respect to the benefits of owning Aion Therapeutic security.